CAR-T Therapies

Dr Bijal Shah
Videos
Bijal Shah, MD, Discusses the Future of KTE-X19 CAR-T Therapy for R/R B-ALL
06/24/2021
In part 2 of this video series, Dr Shah, discusses the next steps of the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 2 of this video series, Dr Shah, discusses the next steps of the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 2 of this video series,...
06/24/2021
Oncology
Videos
KTE-X19 CAR-T Therapy Demonstrates Clinical Benefit for R/R B-ALL
06/08/2021
In part 1 of this video series, Bijal Shah, MD, shares results from the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 1 of this video series, Bijal Shah, MD, shares results from the phase 2 ZUMA-3 study of KTE-X19 for R/R B-ALL. These data were presented at the 2021 ASCO Annual Meeting.
In part 1 of this video series,...
06/08/2021
Oncology
Prophylactic Tocilizumab Before Anti-CD19 CAR-T Therapy for R/R Lymphoma
Videos
Prophylactic Tocilizumab Before Anti-CD19 CAR-T Therapy for R/R Lymphoma
12/09/2020
Paolo Caimi, MD, discusses findings from a study examining the use of prophylactic tocilizumab prior to anti-CD19 CAR-T therapy for relapsed/refractory lymphoma.
Paolo Caimi, MD, discusses findings from a study examining the use of prophylactic tocilizumab prior to anti-CD19 CAR-T therapy for relapsed/refractory lymphoma.
Paolo Caimi, MD, discusses...
12/09/2020
Oncology
Anti-BCMA CAR-T Therapy With bb2121 for Relapsed/Refractory MM
Videos
Anti-BCMA CAR-T Therapy With bb2121 for Relapsed/Refractory MM
09/28/2020
In this video, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
In this video, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
In this video, Dr Raje discusses...
09/28/2020
Oncology
Videos
CAR T-Cell Therapy: Where Do We Stand in 2019?
11/13/2019
Thomas Kipps, MD, PhD, gives an update on the development of CAR T-cell therapy at the 2019 Lymphoma & Myeloma Congress.
Thomas Kipps, MD, PhD, gives an update on the development of CAR T-cell therapy at the 2019 Lymphoma & Myeloma Congress.
Thomas Kipps, MD, PhD, gives an...
11/13/2019
Oncology
Podcasts
The Use of CAR-T Therapy for B-Cell Lymphomas Outside of Clinical Trials
12/25/2018
Jonathon Cohen, MD, discussed a trial presented at the ASH Annual Meeting on real world results of axicabtagene ciloleucel in B-cell lymphomas.
Jonathon Cohen, MD, discussed a trial presented at the ASH Annual Meeting on real world results of axicabtagene ciloleucel in B-cell lymphomas.
Jonathon Cohen, MD, discussed a...
12/25/2018
Oncology
Real-World Results Support Axi-Cel Use in B-Cell Lymphomas Outside of Clinical Trials
12/12/2018
Results from a real-world trial show that axicabtagene ciloleucel can be used outside of clinical trial settings, although outcomes may differ.
Results from a real-world trial show that axicabtagene ciloleucel can be used outside of clinical trial settings, although outcomes may differ.
Results from a real-world trial...
12/12/2018
Oncology
News
Anti-CD19 CAR-T Therapy Safe, Effective in Large B-Cell Lymphoma
12/05/2018
A follow-up analysis of the ZUMA-1 trial reported 51% of patients receiving axicabtagene ciloleucel were still alive 2 years after treatment.
A follow-up analysis of the ZUMA-1 trial reported 51% of patients receiving axicabtagene ciloleucel were still alive 2 years after treatment.
A follow-up analysis of the...
12/05/2018
Oncology
News
CD19-Targeting CAR-T Therapy Yields Long-Term Response in DLBCL
11/26/2018
In heavily pretreated older adults with relapsed or refractory DLBCL, tisagenlecleucel yielded a high frequency of durable responses, according to study data presented at ASH 2018.
In heavily pretreated older adults with relapsed or refractory DLBCL, tisagenlecleucel yielded a high frequency of durable responses, according to study data presented at ASH 2018.
In heavily pretreated older...
11/26/2018
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use